Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer

Am J Med. 1995 Apr;98(4):412-4. doi: 10.1016/S0002-9343(99)80323-4.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Androgens / agonists*
  • Flutamide / administration & dosage
  • Flutamide / pharmacology*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prostate-Specific Antigen / blood
  • Prostate-Specific Antigen / drug effects*
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / immunology*
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / pathology
  • Receptors, Androgen / drug effects*
  • Treatment Outcome

Substances

  • Androgens
  • Receptors, Androgen
  • Flutamide
  • Prostate-Specific Antigen